MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that the U.S. Patent Office has upheld the validity of two additional patents for human embryonic stem cells (hESCs) that were challenged through reexamination proceedings.
